BCYC · Bicycle Therapeutics plc

0001104659-26-052117

Summary

Narrower operating losses and improved cash burn reflect cost discipline amid 91% revenue decline from ended collaborations, with strategic reprioritization positioned to further reduce near-term expenses and extend cash runway.

Key takeaways

Revenue declined 91% to $887K from $10M YoY, reflecting end of Genentech and Novartis collaborations.
Diluted EPS improved to -$0.87 from -$0.88 YoY.
Operating cash use improved to $65.9M from $86.4M, supporting cash preservation efforts.
Workforce reductions and March 2026 reprioritization are expected to decrease R&D, G&A, and overall expenses in the near term.

Full analysis

Bicycle Therapeutics reported Q1 FY2026 results reflecting disciplined cost management amid significantly reduced revenue. Revenue fell 91.1% to $887K from $9.98M in the prior year quarter, primarily due to the termination of collaborations with Genentech in August 2025 and Novartis in February 2026. This topline pressure underscores a strategic pivot in the company's pipeline focus, shifting resources toward higher-priority programs.